TEST

  • 12/15/2020

    Partner press release: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™

  • 12/01/2020

    DR. JUERGEN BECK WILL LEAVE THE PAION AG MANAGEMENT BOARD ON 31 DECEMBER 2020 AS PLANNED

  • 11/19/2020

    PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA

  • 11/11/2020

    PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2020

  • 10/22/2020

    PAION Insights Newsletter October 2020

  • 10/06/2020

    PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.

  • 08/12/2020

    PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2020

  • 08/11/2020

    PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA

  • 08/07/2020

    PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA

  • 08/03/2020

    PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE PROGRAM FOR REMIMAZOLAM IN BELGIUM

  • 07/29/2020

    Partner press release: Hana Pharm held a groundbreaking ceremony on July 2020 to celebrate the start of the new facility

  • 07/15/2020

    U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA

  • 07/08/2020

    PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES

  • 07/02/2020

    PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION

  • 06/02/2020

    PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE FOR REMIMAZOLAM IN ITALIAN HOSPITAL

  • 05/13/2020

    PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2020

  • 04/02/2020

    PAION CLOSES ENROLLMENT IN EU PHASE III TRIAL WITH REMIMAZOLAM IN GENERAL ANESTHESIA

  • 03/26/2020

    PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2019

  • 03/12/2020

    PAION AG: COSMO ANNOUNCES BRIEF EXTENSION OF FDA REVIEW PERIOD FOR NDA FOR REMIMAZOLAM

  • 01/10/2020

    Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma, takes an initial 14.1% stake and provides finance for Acacia Pharma’s US expansion

  • 01/08/2020

    PAION GRANTS REMIMAZOLAM LICENSE FOR SOUTHEAST ASIA TO HANA PHARM